Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD34+ cells-Alliance for Clinical Trials in Oncology
- Development stage
- Unknown
- Lead developer
- Cancer and Leukemia Group B
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
CD34+ cells-Alliance for Clinical Trials in Oncology refers to a cellular therapy product consisting of CD34-selected hematopoietic stem cells derived from peripheral blood. Developed by the Alliance for Clinical Trials in Oncology, this product is utilized in a Phase II clinical trial protocol for patients with multiple myeloma. The treatment strategy involves an initial autologous stem cell transplantation to facilitate hematopoietic recovery after high-dose chemotherapy (melphalan), followed by a non-myeloablative allogeneic stem cell transplantation to induce a graft-versus-tumor effect. CD34 is a surface glycoprotein and a well-established marker for hematopoietic stem and progenitor cells, which are responsible for reconstituting the immune and blood systems.
- Other names
- CD34+ cellsautologous CD34-selected peripheral blood stem cellsallogeneic CD34-selected peripheral blood stem cellsCD34+ hematopoietic stem cells
Beyond the preview
Go deeper on CD34+ cells-Alliance for Clinical Trials in Oncology.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD34+ cells-Alliance for Clinical Trials in Oncology.